Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events: An Assessment from the Payer's Perspective

Author： Heeg Bart  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.12, 2007-01, pp. : 1063-1082

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral Antiplatelet Therapy in the Secondary Prevention of Atherothrombotic Events

By Ling Geoffrey  

American Journal of Cardiovascular Drugs, Vol. 9, Iss. 3, 2009-05 ,pp. : 197-209

Adis International

Access to resources Recommend Favorite

Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents

By  

Current Pharmaceutical Design, Vol. 18, Iss. 6, 2012-02 ,pp. : 850-860

Bentham Science Publishers

Access to resources Recommend Favorite

Antiplatelet therapy in secondary stroke prevention

By Crawford K Michelle   Talbert Robert L  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 10, 2001-10 ,pp. : 1609-1613

Informa Healthcare

Access to resources Recommend Favorite

Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?

By  

Current Pharmaceutical Design, Vol. 19, Iss. 21, 2013-06 ,pp. : 3788-3794

Bentham Science Publishers

Access to resources Recommend Favorite

Atorvastatin: A Pharmacoeconomic Review of its Use in the Primary and Secondary Prevention of Cardiovascular Events

By Plosker Greg L.   Lyseng-Williamson Katherine A.  

PharmacoEconomics, Vol. 25, Iss. 12, 2007-01 ,pp. : 1031-1053

Adis International

Access to resources Recommend Favorite